 Xenon Pharmaceuticals Inc NASDAQ: XENE has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency compared to placebo. 